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The periodic paralysis (PP) are rare autosomal-dominant disorders associated to mutations in the 
skeletal muscle sodium, calcium, and potassium channel genes characterized by muscle fiber 
depolarization with un-excitability, episodes of weakness with variations in serum potassium 
concentrations. Recent advances in thyrotoxic PP and hypokalemic PP (hypoPP) confirm the 
involvement of the muscle potassium channels in the pathogenesis of the diseases and their 
role as target of action for drugs of therapeutic interest. The novelty in the gating pore currents 
theory help to explain the disease symptoms, and open the possibility to more specifically target 
the disease. It is now known that the fiber depolarization in the hypoPP is due to an unbalance 
between the novel identified depolarizing gating pore currents (Igp) carried by protons or Na
+ 
ions flowing through aberrant alternative pathways of the mutant subunits and repolarizing 
inwardly rectifying potassium channel (Kir) currents which also includes the ATP-sensitive 
subtype. Abnormal activation of the Igp or deficiency in the Kir channels predispose to fiber 
depolarization. One pharmacological strategy is based on blocking the Igp without affecting normal 
channel gating. It remains safe and effective the proposal of targeting the KATP, Kir channels, or 
BK channels by drugs capable to specifically open at nanomolar concentrations the skeletal 
muscle subtypes with less side effects.
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the attacks. The attacks are triggered by rest after strenuous exer-
cise, by a meal rich in carbohydrates, or by exposure to cold. The 
glucose-dependent insulin release from pancreatic beta cells or 
insulin injection is one of the most effective provocative factors 
in the human disease. Patients typically wake up paralyzed, and 
attacks usually last several hours to days in the severe cases. In the 
elderly, the patients develop progressive, persistent weakness that 
takes the form of a proximal myopathy.
Andersen’s syndrome is characterized by a unique phenotype 
consisting of PP, cardiac arrhythmias, facial and skeletal malfor-
mations. The disease was firstly discovered by Ellen Andersen in 
the 1971 but it has been clinically characterized latter on by Al 
Rabi Tawil (Andersen et al., 1971; Tawil et al., 1994). Paralysis may 
occurs with either hyperkalemia or hypokalemia that exacerbate 
the cardiac arrhythmia. Heart manifestations include ventricular 
arrhythmia (84% of patients), long QT syndrome (50% of patients), 
abnormal TU wave patterns (73%), and sudden cardiac arrest (10% 
of patients). A bidirectional ventricular tachycardia (BVT) is a char-
acteristic rhythm disturbance present only in AS, digitalis intoxica-
tion, and ryanodine receptor mutations (Morita et al., 2007).
Thyrotoxic PP is a sporadic muscle disorder characterized by 
episodic attacks of weakness and hypokalemia in some, but not all, 
thyrotoxic individuals. Patients are normal between attacks, which 
resolve with treatment of thyrotoxicosis. The adrenergic symptoms 
potentiated by the abnormal thyroide hormone release play a mayor 
role in the disease. Episodic weakness in TPP is clinically similar to 
the hypoPP and AS. It is the most common form of PP being most 
prevalent in young Asian and Latin American men, about 10% of 
INTRODUCTION
The primary periodic paralysis (PP) are rare autosomal-dominant 
disorders associated to mutations of the skeletal muscle sodium, 
potassium, and calcium channel genes. They are characterized by 
episodes of muscle weakness associated with variations in serum 
potassium concentration. The primary PP are classified as hyper-
kalemic PP (hyperPP), hypokalemic PP (hypoPP), and Andersen’s 
syndrome (AS; Platt and Griggs, 2009). Other related disorders are 
the thyrotoxic PP (TPP) associated with thyrotoxicosis.
HyperPP is characterized by attacks of flaccid limb paralysis 
with weakness associated with abnormally elevated serum K+ ions 
levels up to 6 mEq/L. Triggers for these attacks are ingestion of 
potassium-rich food, rest after strenuous exercise, and cold expo-
sure. Episodes of weakness may last for up to an hour and disappear 
as the blood potassium concentration decreases. Attacks typically 
begin in the first decade of life, increase in frequency and severity 
during puberty, and then decrease in frequency after 40 years of age. 
Myotonia of the extremities supports the diagnosis of hyperPP.
Hypokalemic PP is generally characterized by reversible attacks 
of muscle weakness associated with decreased blood potassium 
concentrations below 3.2 mEq/L. In the most severe cases the 
blood potassium concentration decrease below 1 mEq/L during 
Abbreviations: AS, Andersen’s syndrome; BK, Ca2+activated K+ channels; hyperPP, 
hyperkalemic periodic paralysis; hypoPP, hypokalemic periodic paralysis; I
gp
, gating 
pore currents; I
KDR
, the delayed rectifier; I
Kir
, Inwardly rectifier currents; K
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, ATP-
sensitive K+ channels; Kir, Inwardly rectifier K+ channels; PP, periodic paralysis; TPP, 
thyrotoxic periodic paralysis.
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skeletal muscle calcium channel, Cav1.1 (hypoPP type-1) and the 
α-subunit of the Nav1.4 channel (hypoPP type-2). Missense muta-
tions were first identified in the calcium channel gene, CACNA1S, 
which accounts for approximately 60% of cases (Jurkat-Rott et al., 
1994; Ptacek et al., 1994). In hypoPP type-2 10% of the cases are 
due to mutations in the sodium channel gene, SCN4A (Jurkat-Rott 
et al., 2000; Sternberg et al., 2001). Phenotypic differences between 
hypoPP-1 and hypoPP-2 include:
(1) earlier onset of disease in HypoPP-1;
(2) myalgias in hypoPP-2;
(3) predominance of tubular aggregates in hypoPP-2 and vacuo-
les in hypoPP-1 in muscle biopsy;
(4) aggravation of hypoPP-2 by acetazolamide.
In hypoPP-1 the mutations of the Cav1.1-DHP receptor genes 
replace arginine residues in the S4 voltage sensor in domains II, 
III, or IV with neutral amino acids with loss-of-function mutations 
(Jurkat-Rott et al., 1994; Ptacek et al., 1994; Lapie et al., 1996). 
Similarly, in hypoPP-2 previous works showed that sodium channel 
mutations cause a loss-of-function by enhancing channel inactiva-
tion, mainly by stabilizing the inactivated state (Jurkat-Rott et al., 
2000; Sternberg et al., 2001; Kuzmenkin et al., 2002). Mutations 
specifically target positively charged arginine residues in the S4 
voltage sensor in domains II or III, which triggers voltage sen-
sor dysfunction. These findings suggested that the pathological 
effects of these mutations in hypoPP-1 and hypoPP-2 are caused 
by voltage sensor dysfunction and impaired channel gating with 
impairment of the excitation–contraction coupling. We can say 
that these mutations are essentially loss-of-function of Cav1.1 and 
Nav1.4 channels.
However, the general idea is that this theory does not account for 
the sarcolemmal depolarization or the hypokalemia and paralysis 
induced by insulin and glucose during the attacks that characterize 
hypoPP phenotype.
Involvement of K+ channels in the hypoPP pathogenesis
Kir channels have a key role in the pathogenesis of hypoPP. Kir 
currents carried by the inwardly rectifier K+ channels which also 
include the ATP-sensitive type set the resting potentials close to 
the equilibrium potentials for K+ ions which is around −90 mV 
as calculated by Nernst equation in normal fibers. The inwardly 
rectifier K+ channels show a non-linear I–V curves with high 
permeability to K+ ions at negative membrane potentials which 
generates an elevated inward currents, and lower permeability at 
depolarized potentials generating much lower outward currents. 
This graphically generates an hump of the I–V curves which is 
an intrinsic properties of the Kir channel currents (Figure 1A). 
This is caused by the internal Mg2+ ions, polyamines and proton-
block of the pore at millimolar concentrations which compete 
with K+ ions for the internal pore binding sites (Figures 1A,B). The 
blocking actions of these positively charged molecules and ions is 
voltage-dependent being more effective at depolarizing voltages. A 
potential gradient across the cell membrane removes this block-
age during hyperpolarization but allow these cations to occlude 
the ion-conducting pore during depolarizations (Hibino et al., 
2009). Rectification is important for setting the resting potential 
thyrotoxic males develop episodic weakness. In Caucasians, is less 
than 0.1. Although thyrotoxicosis is more common in women, most 
individuals with TPP are men.
Secondary forms of PP are also known and are normally associ-
ated with hypokalemia caused by depletion of serum K+ ions associ-
ated with a K+ free diet or malnutrition, licorice intoxication, lassative 
and diuretic abuse, digitalis intoxication, barium intoxication, beta-2 
agonists abuse in asthmatic patients or insulin overdose in diabetic 
patients. Clinical signs such as weakness, flaccid paralysis, and cardiac 
dysrhythmia are normally transient and their severity is dependent on 
the serum K+ ions levels reached during the attacks. The clinical signs 
may be permanent in those conditions associated with K+ free diet 
as observed in the K-depleted rats or malnutrition. The K-depleted 
rats, in the absence of transgenic animals, is considered a valid ani-
mal model of the familial hypoPP resembling the human phenotype. 
This is obtained by feeding the animals for 14–18 days with a K+ free 
diet (Tricarico et al., 1998). These animals show the flaccid paraly-
sis induced by glucose/insulin injection, the vacuolar myopathy and 
tubular aggregates in the muscle biopsies, the serum K+ ions levels 
between 1 and 2 mEq/L during the attacks. However, in contrast to 
patients affected by the familial hypoPP in which the serum K+ ions 
levels between the attacks is normal, the K-depleted rats have a general 
weakness associated with serum K+ ions levels below 3.2 mEq/L even 
between the attacks. Secondary hyperkalemia is observed following 
glucocorticoids infusions or K+ sparing diuretic abuse. KCl (3–5%) 
solution infusion overdose is the most frequent and dangerous form 
of induced hyperkalemia in humans even leading to fatal arrhythmias. 
This have led to alerts managing this type of drugs.
PATHOGENESIS OF PERIODIC PARALYSIS
PATHOGENESIS OF HYPERPP
In hyperPP the pathomechanism is well established and it is 
explained by the gain-of-function mutations in the α-subunit of the 
skeletal muscle voltage-gated sodium channel, Nav1.4. The T704M 
and M1592V mutations in the SCN4A gene account for the major-
ity of cases. The mutant channels show failure of the inactivation 
process which results in continual sodium influx and persistent cell 
depolarization; stronger and persistent depolarization in hyperPP 
leads to general inactivation of sodium channels and depolarization 
block, which manifests as paralysis (Jurkat-Rott and Lehmann-
Horn, 2007). The sustained membrane depolarization in hyperPP 
amplifies K+ ions efflux from the muscle through voltage-dependent 
K+ channels. The enhanced activity of the voltage-dependent K+ 
channels elevate the serum K+ ions concentration.
Sporadic cases of patients have however normal serum potas-
sium levels during attacks of weakness. Some of the families carry 
hyperPP mutations resulting as a phenotypic variant of hyperPP, 
some others carry unique mutations of the R3 gating charge in 
the voltage sensor of domain 2 of the Nav1.4 channel. Patients 
from these families have phenotypes similar to hypoPP, others have 
phenotypes similar to hyperPP with weakness induced by K+ ions 
supplementation (Vicart et al., 2005).
PATHOGENESIS OF HYPOPP
The pathomechanism of hypoPP has been debated from many 
years but only recently has been clearly elucidated. HypoPP has 
been associated with mutations in both the α1-subunit of the 
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channel opening is related with the reductions of the binding affin-
ity of the channel to PtdIns(4,5)P2 interaction. This is observed 
at pH values of about 6.5 (Qu et al., 2000; Hibino et al., 2009). 
Pharmacological investigations support the involvement of the Kir 
channels in hypoPP. Barium toxicity produces a secondary form 
of hypoPP, and the Kir channel is blocked by Ba2+.
However other than Kir block by protons also a down-regulation 
of the Kir subunits due to low-external K+ ions levels appear to 
be responsible for hypoPP. Abnormal reduction of K
ATP
 channel 
activity has been reported in excised patches from human hypoPP 
fibers with the CaV1.1-R528H mutation and in muscle fibers from 
K-depleted rats (Tricarico et al., 1998, 1999b). These channels 
show several subconductance states with lower open probability 
as compared with that recorded in human biopsies from healthy 
subjects and control rats. The “in vitro” administration of insulin 
to muscle fibers from K-depleted rats and human hypoPP patients 
reduced the Kir currents and the K
ATP
 currents making them more 
and aiding in  repolarization of cells while shunting K+ currents 
during depolarizations allowing it. In normal fibers the lowering 
of external K+ ions from 4 to 2.5 mEq/L shift the I–V relationships 
of Kir currents and of total membrane currents to the left toward 
more negative values as predicted by the Nernst equation (Figure 
1A; Cannon, 2010). However, the lowering of ext. K+ ions below 
1.5 mEq/L reduces Kir outward currents shifting the I–V relation-
ships of Kir currents and of total membrane currents to the right 
toward more positive values setting the resting potential at a new 
depolarized values. This is also called paradoxical membrane depo-
larization in low ext. K+ ions concentrations which is explained by 
the enhanced affinity of the Mg2+ ions and polyamines or protons 
for their inhibitory binding sites unmasked by the extremely low 
ext. K+ ions concentration (Figures 1 and 2; Hibino et al., 2009; 
Cannon, 2010). This is an intrinsic property of the Kir channel 
that play a key role in the pathogenesis of hypoPP and related 
diseases. One mechanism by which low intracellular pH inhibit 
FIGURE 1 | Steady-state I–V relationships simulation in normal and hypoPP 
conditions, and molecular architecture of a Kir channel [modified from 
Kurachi and colleagues (Hibino et al., 2009) and Cannon (2010)]. The I–V 
relation for mammalian skeletal muscle was simulated by the combination of an 
inward rectifier K+ current, IKir, a delayed rectifier K
+ current, IKDR, and a leakage 
current with a reversal potential of 0 mV, ILeak (A). In 4 mM [K
+]o the resting 
potential of −91.3 mV is determined primarily from the balance of an inward ILeak 
and outward IKir. Addition of a gating pore current, Igp, to simulate hypoPP 
(dashed red line), shifts the I–V relation downward (dashed black line) but results 
in only a small depolarization of Vrest to −87.3 mV. The reduction of [K
+]o to 
2.5 mM shifts EK and IKir to more negative potentials, with a predicted 
hyperpolarization of Vrest to −101.6 mV in WT fibers. For hypoPP fibers, however, 
Vrest depolarizes to −65.3 mV (arrow) because the combination of inward 
currents (ILeak + Igp) exceeds the outward current from IKir. Modified from the 
original version of Cannon (2010) to evidence that in low external K+ ions the 
affinity of Mg2+ions, protons and other endogenous blockers of Kir channels for 
their inhibitory sites increase leading to the characteristic hump in the I–V 
relationship of the Kir current component. (B) A schematic representation of the 
structure of a generic Kir channel. The Kir channel is divided into transmembrane 
and cytoplasmic domains. The NH2 and COOH termini are cytosolic. Tetrameric 
assembly of Kir channels. The molecular architecture of a tetrameric Kir channel 
(protein database ID 2QKS: Kir3.1–KirBac3.1 chimera) is represented as a 
cartoon model reproduced and modified from Kurachi and colleagues (Hibino 
et al., 2009). The front subunit has been omitted for clarity. The organization of 
the tetramer of NH2 and COOH termini leads to an extended pore for ion 
permeation. The transmembrane domain comprises three helices: TM1, H5, and 
TM2. At the membrane–cytoplasm interface, there is also an amphiphilic slide 
helix which is a site for some AS mutations. The residue that is largely 
responsible for the interaction with polyamines and Mg2+ and thus inward 
rectification are located on TM2. In Kir6.2, the inhibitory binding sites for ATP are 
located in the cytoplasmic domains. TM1 contains the inhibitory binding sites for 
protons in the Kir1.1. Inhibitory sites for protons in other Kir channels as Kir2.3 
are located also in the cytoplasmic regions affecting PiP2 binding. The opening 
of Kir channels requires PtdIns(4,5)P2 (PiP2). Those amino acid residues 
associated with the interaction with PiP2 are distributed on the surface of the 
cytoplasmic domain toward the plasma membrane. These are also the sites for 
most of the AS mutations in the Kir2.1. The cytoplasmic domain also contains 
most of the TPP mutations recently found in the Kir2.6.
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tials (Sokolov et al., 2007; Cannon, 2010). The gating pore cur-
rents from IIS4-R1H and IIS4-R2H hypoPP mutations were carried 
exclusively by protons, whereas the gating pore currents produced 
by non-histidine mutations at IIS4-R2G/C/S/Q were permeable to 
alkali metal cations (K+ ≈ Cs+ > Na+ ≈ Li+) and guanidinium were 
active at hyperpolarized potentials resulting in a poor selectivity 
among monovalent cations with important pathophysiological 
implications (Cannon, 2010). In normokalemic PP (normoPP) 
some mutations in the R3 gating charge producing gating pore cur-
rent were activated by depolarization leading to abnormal persistent 
sodium influx and depolarization of the muscle fiber (Sokolov et al., 
2008). Jurkat-Rott et al. (2009) in their works demonstrated that 
a sodium overload is occurring in muscle biopsies from hypoPP 
and normoPP patients either by direct entry of sodium through 
the gating pore channels or by increased sodium influx through 
hyperactivation of the sodium–proton exchanger that transform 
the proton leak into a Na+ leak.
In hypoPP-1 Kuzmenkin et al. (2007) showed that Cav1.1 
mutants stabilize the second open state of the calcium channel and 
proposed that the low selectivity of the channel in this state would 
allow monovalent ions to pass into the cell and promote depolariza-
tion. As in hypoPP-2 the mutations replace arginine residues in the 
S4 voltage sensor in domains II, III, or IV with neutral amino acids 
leading to the muscle paralysis syndrome with progressive myopa-
thy. This hypothesis could account for the common downstream 
phenotype of the periodic paralyses. However, currently there is 
no experimental evidence to support it for technical limitations 
in recordings these types of I
gp
 currents even in cell lines over-
expressing Cav1.1 mutants (Cannon, 2010).
In hypoPP mutants the abnormal activation of the inward 
cationic I
gp
 currents increases the susceptibility of the fibers to the 
depolarization. Indeed, the membrane currents is the sum of at 
least 3 components: the inwardly rectifier currents (I
Kir
), the delayed 
rectifier (I
KDR
), the passive leak that reverse at 0 mV and in hypoPP 
the gating pore (I
gp
).
I
memb
 = I
Kir
 + I
KDR
 + I
Leak
 + I
gp
As a result, the resting potential is determined by a balance 
of two relatively small currents, the outward component of the 
I
Kir
 and the inward I
Leak
. While I
KDR
 is a gating/voltage-dependent 
currents involved at depolarized potentials which is carried by 
K
v
 and BK channels. The cationic inward I
gp
 is summed to the 
I
Leak
 exceeding the outward I
Kir
. This is observed at 3–3.5 mEq/L 
concentrations of K+ ions much closer to the physiological range 
(4–6 mEq/L) (Cannon, 2010). Because the Kir currents coun-
terbalance the depolarizing I
gp
 and leak currents, the Mg2+ and 
polyamine or proton dependent depolarization-block of the Kir 
channels in addition to the I
gp
 currents leads to depolarization 
of few millivolts setting the resting potentials to a new values of 
about −60 mV (V
m
; Figure 1A). The action potential generation 
from this new level result in weakness and paralysis. Jurkat-Rott 
et al. (2009) showed that muscle fibers from healthy subjects and 
hypoPP patients have bimodal distribution of membrane poten-
tials with two values of >−75 mV (P1) and −60 mV (P2; V
m
). 
However, hypoPP muscle fibers show an higher frequency of find-
ing fibers at P2 membrane potentials than controls (Jurkat-Rott 
et al., 2009). Taken together, these observations suggest that attacks 
 susceptible to aberrant depolarization (Ruff, 1999; Tricarico et al., 
1999a). Reduced channel open probability and single channel con-
ductance has been reproduced “in vitro” following short term expo-
sure (80 min) of the rat fibers to low external K+ ions (0.5 mEq/L) 
suggesting that an extremely low levels of K+ ions block the Kir6.2 
channel of normal rats (Tricarico et al., 1999b). More recently, we 
demonstrated that in K-depleted rats the impaired K
ATP
 activity is 
associated with a reduced expression of SUR2A and Kir6.2 subu-
nits composing the main K
ATP
 channel complex in skeletal muscle 
(Tricarico et al., 2008a). Case reports showed that patients suffering 
from hypoPP have reduced expression of the Kir6.2 subunit and/
or abnormal membrane localization of SUR2A suggesting defect 
in membrane trafficking of this subunit (Jovanovic et al., 2008; 
Kim et al., 2010).
Gating pore current hypothesis in the hypoPP pathogenesis
Recently, several researchers have suggested a new pathomecha-
nism to explain hypoPP-2 and possibly hypoPP-1. Catterall and 
colleagues (Sokolov et al., 2007) firstly showed that three com-
mon hypoPP-2 mutations induced a hyperpolarization-activated 
cationic leak current through the voltage sensor of the sodium 
channel, which they called “gating pore current” (Sokolov et al., 
2007). According to their model, hypoPP-2 mutations are essen-
tially gain-of-function because the cation leak increases resting 
membrane conductance and sodium influx, leading to excessive 
depolarization. Struyk and Cannon (2007) initially found that the 
gating pore permitted transmembrane permeation of protons. The 
predicted magnitude of this leak was not large enough to produce 
aberrant depolarization by itself, but the authors theorized that 
sustained proton leak could indirectly contribute to instability of 
the resting membrane potential by interfering with pH balance 
inside the cell. More recently these and others shown that all five 
hypoPP mutations in IIS4 screened by expression studies in oocytes 
produced gating pore currents activated at hyperpolarized poten-
FIGURE 2 | Proposed cascade of the pathogenic events in the 
hypokalemic periodic paralysis. The unbalance between the depolarizing 
and repolarizing current components is due to an abnormal activation of 
depolarizing gating pore currents (Igp) with increased influx of protons or Na
+ 
ions through mutants and to the abnormal reduction of the repolarizing Kir 
currents carried by various subtypes of Kir channels. The insulin/glucose 
administration induces activation of the 3Na+/2K+-ATPase but failed to activate 
KATP channels causing a marked hypokalemia. The hypokalemia reduces the 
gene expression/activity of the Kir6.2 and SUR2A subunits. All these factors 
contribute to the fiber depolarization setting the resting potentials to a new 
value of −60 mV (Vm). The depolarization of the fibers inactivates the 
voltage-dependent Na+ and Ca2+ channels with paralysis.
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 channel function; the loss-of-function mutations in AS have been 
linked to decreased PIP2 sensitivity and an exaggerated inhibi-
tory effects of intracellular Mg2+ or protons (Figure 1B). Another 
mechanism involves dysfunction of a portion of the channel known 
as the slide helix, which represents a cluster point for AS mutations. 
It is thought that interaction of the slide helix with the C-terminus 
is required for normal gating of the Kir2 family of channels. Skeletal 
muscle dysmorphisms can be explained by mutations of Kir2.1. 
This channel is active in differentiating cells inducing hyperpo-
larization and setting the E
m
 in a range where Ca2+can enter the 
myoblasts through Ca2+-permeable channels, which promotes the 
differentiation and fusion of myoblasts. Differentiation is at least in 
part mediated by expression and activity of myogenic transcription 
factors, such as myogenin and myocyte enhancer factor-2. Their 
expression is triggered by Kir2.1-induced hyperpolarization. In 
addition, abnormal bone structure in the disease would be caused 
by provoking dysfunction of osteoclasts. Low extracellular pH in 
the extracellular matrix maintained by H+ secretion via an ATP-
driven proton pump is critical for proper degradation of bone 
by osteoclasts. Since this H+ secretion is achieved in exchange for 
K+ transport through Kir channels, disruption of these channels 
would cause osteoclast dysfunction that could lead to severe bone 
deformity. As demonstrated in Kir2.1 knockout mice that exhibit 
a narrow maxilla and complete cleft of the secondary palate that 
may mimic the facial dysmorphology observed in humans (Hibino 
et al., 2009).
PATHOGENESIS OF THYROTOXIC PERIODIC PARALYSIS
In TPP, the muscle PP has been linked to mutations of the 
inwardly rectifying potassium channel called Kir2.6 encoded by 
a new KCNJ18 gene (Figure 1B; Ryan et al., 2010). Ryan et al. 
(2010) demonstrated that some TPP mutants show decreased 
current density at −60 mV (V
m
), some others lack the modulation 
by PKC which is normally activated during thyrotoxicosis leading 
to inhibitory action of WT channels but not mutants. Another 
effects of some mutations is to reduce the binding affinity for 
PiP2 (Figure 1B). This leads to abnormally prolonged channel 
openings uncoupled to PiP2. Protein regulation by thyroid hor-
mones occur by transcriptional and post-translational events. 
Transcriptional regulation is particularly important in skeletal 
muscle, where both decreased (hypothyroidism) and increased 
(thyrotoxicosis) T3 has a profound effect on muscle performance. 
Several ion channels as Kv1.5 and Kv4.2 and now also Kir2.6 
channels are known to be transcriptionally regulated by T3 
through the thyroid response elements on the genes. Increased 
or decreased ion channel transcription during thyrotoxicosis may 
cause drastic changes in resting membrane potential and potas-
sium accumulation and can lead to weakness in otherwise normal 
patients. The Kir2.6 levels are increased during thyrotoxicosis 
to aid in proper membrane potential maintenance, warding off 
more severe weakness. For instance increased Kir currents of 
some mutants during thyrotoxicosis may lead to hyperpolariza-
tion and difficulty to reach the threshold potentials with altered 
excitability. As opposite the reduced current density in some 
other TPP mutants lead to depolarization and inactivation of 
voltage-dependent Na+ and Ca2+ channels with weakness and 
paralysis (Ryan et al., 2010).
of hypoPP triggered by carbohydrate ingestion is linked to insulin 
secretion with the attendant reduction of Kir currents specifically 
from an increased intracellular ratio of [ATP]/[ADP] which would 
inhibit K
ATP
 channels and of the reduced/expression activity of 
the Kir6.2/SUR2A subunits (Figure 2). A secondary insulin effect 
would be a shift of extracellular K+ ions into the myoplasm from 
increased activity of the 3Na+/2K+-ATPase with uncompensated 
hypokalemia. Both effects, decreased K
ATP
 activity and reduced 
extracellular [K+], contribute to the additional development of 
paradoxical depolarization and weakness which is a consequence 
of the unbalance between the repolarizing Kir/K
ATP
 and depolar-
izing I
gp
 (Figure 2).
Further explanations to the pathogenesis of hypoPP take into 
account other transports systems. Some authors indeed proposed 
that the activity of the sodium–hydrogen exchanger transform the 
influx of proton into a Na+ influx with increased intracellular osmo-
larity, edema, and sodium cytotoxicity (Jurkat-Rott et al., 2009; 
Matthews and Hanna, 2010). While the proton influx activates the 
monocarboxylate transporter that catalyze the efflux of proton and 
lactate with accumulation of these molecules into the t-tubule. 
Vacuoles are indeed a common morphological finding in primary 
and secondary hypokalemic PP. They are localized swelling and 
vacuolation of the t-tubules secondary to increased osmolarity 
caused by the local accumulation of ions or metabolites including 
lactate. The K-depleted rats model demonstrated a vacuolar myopa-
thy associated with an increased efflux of lactate from muscle fibers 
suggesting that this cannot be related to the genotypes (Tricarico 
et al., 2008b; Matthews and Hanna, 2010).
Carbonic anhydrase (CA) enzymes that buffer the intra-/extra-
cellular pH changes have been proposed as an additional factor 
involved in the pathogenesis of PP (Matthews and Hanna, 2010). 
This is supported by the findings that the deleterious effects of 
the arginine–histidine substitutions observed in some expressed 
hypoPP mutants could be ameliorated by a more acidic pH whereas 
the arginine–glycine substitution was insensitive to alterations in 
pH (Kuzmenkin et al., 2002). However, against the CA involve-
ment in the PP pathogenesis is the notion that the intracellular 
acidification would block several K+ channels as Kir or even BK 
channels and would activate carrier transports as above reported 
with deleterious effects.
PATHOGENESIS OF ANDERSEN’S SYNDROME
In AS, the majority of the patients have loss-of-function mutations 
in the KCNJ2 gene, which encodes the inward rectifier potassium 
channel, Kir2.1 (Plaster et al., 2001; Platt and Griggs, 2009). This 
channel is abundantly expressed in excitable tissues throughout the 
body, and channel dysfunction explain most of the disease symp-
toms including facial and skeletal malformations. The mutations in 
the KCNJ2 gene cause the disease by suppression of outward potas-
sium currents and/or enhancement of inward currents, which can 
occur by dominant negative effects or haplo-insufficiency (Plaster 
et al., 2001). In normal heart and skeletal muscle, the inwardly 
rectifying potassium channel, Kir2.1, stabilizes the resting mem-
brane potential and regulates action potential duration, especially 
in myocytes. Human patients suffer for longer action potentials and 
prolonged Q-T interval, and arrhythmia. Many cellular modula-
tors affect potassium channel activity and are necessary for proper 
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and some have detrimental responses (Bendahhou et al., 2001; 
Sternberg et al., 2001; Kim et al., 2007; Kil and Kim, 2009). One 
explanation is that the gating defects of mutants with a glycine sub-
stitution expressed in cell lines are not alleviated by lowering intra-
cellular pH and therefore the patients affected by these mutations 
would not benefit from acetazolamide, while histidine substitutions 
are alleviated by low pH and patients carrying those mutations 
should benefit from this drug (Kuzmenkin et al., 2002).
Currently no I
gp
 blockers are available for clinical use. Catterall 
and colleagues (Sokolov et al., 2010) recently showed that gating 
pore current generated by Nav1.4 mutants R666H or R666G can 
be blocked by trivalent cations, but in a nearly voltage-independent 
manner, with an apparent K(d) for Gd(3+) of 238 μM at −80 mV. 
They found that an the 1-(2,4-xylyl)guanidinium, an aliphatic gua-
nidine derivative, can block gating pore current in the millimolar 
concentration range without affecting normal Na(V)1.4 chan-
nel function. This demonstrates voltage-dependent and voltage-
independent block by divalent and trivalent cations, respectively, 
and provide initial support for the concept that guanidine-based 
molecules can be the first synthetic gating pore blockers (Sokolov 
et al., 2010).
The treatment of AS is complicated by the necessity of treat-
ing two distinct excitable tissues, skeletal muscle and cardiac 
muscle. For the PP, therapy involves minimizing known triggers 
and prophylaxis against recurrent attacks with the CA inhibitors. 
Potassium supplementation may also prevent paralytic attacks 
MECHANISMS OF DRUG ACTION IN PERIODIC PARALYSIS 
AND DRUG THERAPY
Drug therapies can be separated into two categories, treatments 
used for acute attacks and prophylactic treatments.
In hyperPP, acute attacks may respond to inhaled salbutamol 
or glucose/insulin therapy that exert their repolarizing actions by 
activating the 3Na+/2K+-ATPase and restoring the serum K+ lev-
els. Whereas in hypoPP, acute attacks are usually treated with oral 
potassium chloride glucose-free.
The treatment of the hyperkalemia and hypokalemia in hyperPP 
or hypoPP is achieved with some success by the administration 
of the benzothiazide diuretics as hydrochlorothiazide and of K+ 
sparing diuretics, respectively. But the most effective medica-
tions for the prevention of attacks in both disorders remain the 
CA inhibitors, particularly acetazolamide and dichlorphenamide. 
These drugs ameliorate paralysis reducing the frequency of the 
attacks. One of the main mechanism responsible for the therapeu-
tic effects of these drugs is related to their capability to open the 
muscular calcium-activated potassium channels (Tricarico et al., 
2000, 2004). These drugs activate BK channels in excised patch 
experiments from normal and depleted rat fibers at micromolar 
concentrations indicating that the observed actions are due to a 
direct interaction of the molecules with the channel subunits in 
the isolated membrane (Figure 3). The actions of acetazolamide 
and dichlorphenamide are structure-related; indeed, these mol-
ecules share the same pharmacophoric characteristics of benzimi-
dazolone class of compounds which are well known small synthetic 
BK channel openers (Tricarico et al., 2004). Acetazolamide and 
dichlorphenamide repolarize skeletal muscle fibers and prevent 
muscle paralysis and weakness in K-depleted rats induced by insu-
lin/glucose injection by openings the BK channels (Tricarico et al., 
2006). Acetazolamide at 100 × 10−4 M is also capable to repolarize 
muscle fibers from human hypoPP patients even in the presence 
of low ext. K+ ions (Jurkat-Rott et al., 2009). The effects of aceta-
zolamide and dichlorphenamide on human BK channel have been 
also recently investigated, and we found that these two drugs are 
effective against the hslo channel subunit expressed in HEK293 
cell at submicromolar concentrations being 10 times more potent 
against human channel vs. rat channel. These effects were observed 
at −60 mV (V
m
) justifying their use in the attack prevention rather 
than during the attack of PP (unpublished observations). Currently 
no direct interaction of these drugs with Kir including K
ATP
 chan-
nels have been observed in native fibers or recombinant clones 
expressed in cell lines indicating that acetazolamide by targeting BK 
channel increase the KDR current component thereby shifting the 
control of the resting potential under a voltage-dependent current 
component (Figure 1A).
Acetazolamide has been shown to prevent vacuolar myopathy 
by inhibiting the proton–lactate co-transport in the skeletal muscle 
of K-depleted rats which implies that it may averts the progres-
sive myopathy seen in hypoPP as well as the inter-attack of weak-
ness in humans (Figure 3; Tricarico et al., 2008b; Matthews and 
Hanna, 2010).
However, in some hypoPP patients acetazolamide failed to pre-
vent paralysis and in some cases show detrimental effects. It is 
reported that none of the patients with glycine substitutions, i.e., 
R528G, R1239G, or R672G had benefit by acetazolamide  treatment 
FIGURE 3 | Targets of drug actions of potential interest in the 
hypokalemic periodic paralysis (modified from Matthews and Hanna, 
2010). Acetazolamide or dichlorphenamide are capable to activate the 
calcium-activated K+ channels (BK) at submicromolar concentrations with fiber 
repolarization. Acetazolamide is also capable to inhibit the monocarboxylate 
transporter (MCT) reducing the efflux of lactate thereby preventing vacuolar 
myopathy. This drug also inhibits the membrane bound carbonic anhydrase 
(CA) enzymes with effects on the extra-/intracellular proton exchange 
mechanisms. KATP openers activate the ATP-sensitive K
+ channels (KATP) at 
submicromolar concentrations. Other pumps and co-transports such as the 
natrium-bicarbonate co-transport (NBC), natrium hydrogen exchanger (NHE), 
or sodium–potassium ATPase may have a role in hypoPP pathogenesis are 
however not directly affected by drug actions. Drugs targeting inwardly 
rectifying K+ channels (Kir) can be effective in preventing fiber depolarization 
but are not currently available. Even the novel small synthetic guanidinium 
analogs appear to block at millimolar concentrations the R-H or the R-not H 
mutant subunits of the voltage-dependent Na+ channels but are however far 
from the clinical development.
www.frontiersin.org February 2011 | Volume 2 | Article 8 | 7
Tricarico and Camerino Potassium channels and periodic paralyses
Kuzmenkin, A., Hang, C., Kuzmenkin, E., 
and Jurkat-Rott, K. (2007). Gating of 
the HypoPP-1 mutations: I. Mutant 
specific effects and cooperativity. 
Pflugers Arch. 454, 495–505.
Kuzmenkin, A., Muncan, V., Jurkat-Rott, 
K., Hang, C., Lerche, H., Lehmann-
Horn, F., and Mitrovic, M. (2002). 
Enhanced inactivation and pH 
sensitivity of Na(+) channel muta-
tions causing hypokalaemic periodic 
paralysis type II. Brain 125(Pt 4), 
835–843.
Lapie, P., Goudet, C., Nargeot, J., 
Fontaine, B., and Lory, P. (1996). 
Electrophysiological properties of the 
hypokalaemic periodic paralysis muta-
tion (R528H) of the skeletal muscle 
alpha 1s subunit as expressed in mouse 
L cells. FEBS Lett. 382, 244–248.
Matthews, E., and Hanna, M. G. (2010). 
Muscle channelopathies: does the pre-
dicted channel gating pore offer new 
treatment insights for hypokalaemic 
periodic paralysis? J. Physiol. 588, 
1879–1886.
Morita, H., Zipes, D. P., Morita, S. T., 
and Wu, J. (2007). Mechanism of 
Jurkat-Rott, K., Mitrovic, N., Hang, C., 
Kouzmekine, A., Iaizzo, P., Herzog, 
J., Lerche, H., Nicole, S., Vale-Santos, 
J., Chauveau, D., Fontaine, B., and 
Lehmann-Horn, F.  (2000). Voltage-
sensor sodium channel mutations 
cause hypokalemic periodic paralysis 
type 2 by enhanced inactivation and 
reduced current. Proc. Natl. Acad. Sci. 
U.S.A. 97, 9549–9554.
Kil, T. H., and Kim, J. B. (2009). Severe 
respiratory phenotype caused by a 
de novo Arg528Gly mutation in the 
CACNA1S gene in a patient with 
hypokalemic periodic paralysis. Eur. 
J. Paediatr. Neurol. 14, 278–281.
Kim, J. B., Kim, M. H., Lee, S. J., Kim, D. J., 
and Lee, B.C. (2007). The genotype and 
clinical phenotype of Korean patients 
with familial hypokalemic periodic 
paralysis. J. Korean Med. Sci. 22, 946–951.
Kim, S. J., Lee, Y. J., and Kim, J. B. (2010). 
Reduced expression and abnormal 
localization of the K(ATP) chan-
nel subunit SUR2A in patients with 
familial hypokalemic periodic paraly-
sis. Biochem. Biophys. Res. Commun. 
391, 974–978.
REFERENCES
Andersen, E. D., Krasilnikoff, P. A., and 
Overvad, H. (1971). Intermittent 
muscular weakness, extrasystoles, and 
multiple developmental anomalies. A 
new syndrome? Acta Paediatr. Scand. 
60, 559–564.
Bendahhou, S., Cummins, T. R., 
Griggs, R. C., Fu, Y. H., and Ptácek, 
L. J. (2001). Na channel mutation 
in DIIS4 (Type2 HypoPP), whose 
patients exhibit worsening of the 
phenotype with acetazolamide 
intake: sodium channel inactiva-
tion defects are associated with 
 acetazolamide-exacerbated hypoka-
lemic periodic paralysis. Ann. Neurol. 
50, 417–420.
Cannon, S. C. (2010). Voltage-sensor 
mutations in channelopathies of 
skeletal muscle. J. Physiol. 588, 
1887–1895.
Hibino, H., Inanobe, A., Furutani, K., 
Murakami, S., Findlay, I., and Kurachi, 
Y. (2009). Inwardly rectifying potas-
sium channels: their structure, func-
tion, and physiological roles. Physiol. 
Rev. 90, 291–366.
Jovanovic, S., Du, Q., Mukhopadhyay, S., 
Swingler, R., Buckley, R., McEachen, 
J., Jovanovic, A. (2008). A patient suf-
fering from hypokalemic periodic 
paralysis is deficient in skeletal mus-
cle ATP-sensitive K+ channels. Clin. 
Transl. Sci. 1, 71–74.
Jurkat-Rott, K., and Lehmann-Horn, F. 
(2007). Genotype–phenotype cor-
relation and therapeutic rationale 
in hyperkalemic periodic paralysis. 
Neurotherapeutics 4, 216–224.
Jurkat-Rott, K., Lehmann-Horn, F., Elbaz, 
A., Heine, R., Gregg, R. G., Hogan, K., 
Powers, P. A., Laple, P., Vale-Santos, J. 
E., Weissenbach, J., and Fontaine, B. 
(1994). A calcium channel mutation 
causing hypokalemic periodic paraly-
sis. Hum. Mol. Genet. 3, 1415–1419.
Jurkat-Rott, K., Marc-André, W., Faulera, 
M., Guoa, X., Holzherra, B. D., 
Paczulla, A., Nordsborga, N., Joechle, 
W., and Lehmann-Horn, F. (2009). 
K+-dependent paradoxical membrane 
depolarization and Na+ overload, 
major and reversible contributors to 
weakness by ion channel leaks. Proc. 
Natl. Acad. Sci. U.S.A. 106, 4036–4041.
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sored by Office of Rare Diseases (ORD) and principal investigator 
prof. Rabi Tawil (Platt and Griggs, 2009).
CONCLUSIONS
In conclusion, the unbalance of the depolarizing gating pore cur-
rents and of the repolarizing Kir/K
ATP
 currents explain the paradoxi-
cal depolarization characterizing the hypoPP fibers and predispose 
the fibers to the paralysis induced by glucose/insulin. Currently, the 
gain-of-function of the gating pore proton or Na+ currents flow-
ing through alternative pathways of the mutant subunits has been 
found in the type-2 hypoPP, while a reduced/expression activity 
of K
ATP
 channels and inwardly rectifying potassium channels has 
been found mostly in the type-1 hypoPP.
The three possible targets that have been proposed for the 
treatment of hypoPP are: skeletal muscle selective Kir/K
ATP
 or BK 
openers, gating pore blockers and isoform specific CA inhibitors 
(Figure 3; Matthews and Hanna, 2010).
The recent advance in I
gp
 theory help to explain the PP opening 
the possibility to more specifically target the hypoPP disease. The 
ideal drugs would be the I
gp
 blockers but this appears to be very dif-
ficult to achieve without affecting normal channel gating of the WT 
channels. Na+ channel blockers or Ca2+ channel antagonists failed 
in the treatment of hypoPP and even hyperPP often precipitating 
the attack of weakness indicating that unselective I
gp
 pore blockers 
would precipitate the attacks. It remains safe and effective the pro-
posal of targeting the K
ATP
, Kir channels or BK channels by drugs 
capable to specifically open at nanomolar concentrations the skeletal 
muscle subtypes with less side effects (Tricarico et al., 2008c).
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